Actively Recruiting
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
Led by Mayo Clinic · Updated on 2026-04-27
35
Participants Needed
1
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
CONDITIONS
Official Title
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 30 years or older with exertional dyspnea (NYHA II and III) and left ventricular ejection fraction 50% or higher
- Body mass index (BMI) 30 or higher for HFpEF group
- New diagnosis of HFpEF based on right heart catheterization showing elevated pulmonary capillary wedge pressure at rest or during exercise
- Ambulatory patients aged 18 years or older with confirmed but untreated cardiac sarcoid and positive cardiac 18F-FDG PET scan within 30 days
- Adults aged 30 years or older with no major chronic diseases and no regular intake of relevant medications for healthy control group
You will not qualify if you...
- Primary cardiomyopathy, pericardial disease, or moderate or greater valvular disease for HFpEF group
- Dyspnea caused by lung disease or coronary artery disease
- Severe anemia, liver, or renal disease
- Active cancer
- Systemic active inflammatory or autoimmune diseases such as rheumatoid arthritis or lupus
- Recent hospitalization within 30 days or coronary revascularization within 90 days
- Current use of SGLT2 inhibitors or GLP-1 agonists
- Pregnancy or breastfeeding
- Inability to tolerate lying flat for PET/CT or CMR scans
- Contraindications for safe CMR scanning such as uncontrolled claustrophobia, cochlear implants, or implanted neural stimulators
- Known allergy to gadolinium
- Presence of implantable cardiac pacemaker, defibrillator, or mechanical valve
- Already on immunosuppressive therapy for cardiac sarcoid
- Severe liver or kidney disease with estimated glomerular filtration rate less than 30 or dialysis dependence
- Body mass index 30 or higher for healthy controls
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
J
Jake Nemgar
CONTACT
G
Gregorio Tersalvi, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here